Screener
Relmada Therapeutics, Inc. RLMD Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Payment of fees for issuance of common stock | (3,360,000) | - |
| ATM Fees | (65,651) | - |
| Net cash provided by financing activities | 156,574,345 | - |
| Net increase/(decrease) in cash and cash equivalents | 6,279,860 | (2,707,320) |
| Cash and cash equivalents at beginning of the period | 3,496,540 | 3,857,026 |
| Cash and cash equivalents at end of the period | $9,776,400 | $1,149,706 |
| Non-cash investing and financing activities: | ||
| Cashless exercise of warrants for common stock | (2,082) | - |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s net change in cash?
- Relmada Therapeutics, Inc. (RLMD) reported net change in cash of $6.28M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s net change in cash changed year-over-year?
- Relmada Therapeutics, Inc.'s net change in cash increased by 332.0% year-over-year, from -$2.71M to $6.28M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Relmada Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude